Rapiscan
Authorised
This medicine is authorised for use in the European Union
regadenoson
MedicineHumanAuthorised
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
This is a summary of the European public assessment report (EPAR) for Rapiscan. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rapiscan.
Rapiscan is a solution for injection that contains the active substance regadenoson.
Rapiscan is for diagnostic use only. It is used in a type of heart scan called ‘radionuclide myocardial perfusion imaging’ to see the blood flow in the heart muscle.
Before this type of scan, the patient’s heart is usually put under stress by exercise such as walking or running on a treadmill to help dilate (widen) the blood vessels in the heart and increase the blood flow to the heart muscle. Rapiscan is used as a ‘stress agent’ that has a similar effect on the heart as exercise. It is used in adult patients (aged 18 years or over) who are unable to exercise enough for a stress test.
The medicine can only be obtained with a prescription.
Rapiscan must only be used in a hospital that has equipment for resuscitation and monitoring the patient.
It is given as a 10-second injection of 400 micrograms into a vein immediately followed by an injection of sodium-chloride (salt) solution. The patient then undergoes the procedures for radionuclide myocardial perfusion imaging, starting with an injection of a radioactive substance 10 to 20 seconds after the sodium-chloride injection. Because Rapiscan causes a rapid increase in heart rate and a fall in blood pressure, patients should remain sitting or lying down and be monitored frequently until the effects of the medicine have worn off.
Rapiscan should only be used once within any 24-hour period. Patients must not take any medicines or products that contain methylxanthines (such as caffeine or theophylline) for at least 12 hours before receiving Rapiscan. They should also stop receiving dipyridamole (a medicine used to prevent blood clots) for at least two days before receiving Rapiscan. For further information on the use of Rapiscan, see the summary of product characteristics (also part of the EPAR).
The active substance in Rapiscan, regadenoson, is an A2A-adenosine-receptor agonist. It works by attaching to A2A adenosine receptors in the walls of the blood vessels in the heart, causing the blood vessels to widen and increasing blood flow into the heart muscle. This enables the blood flow in the heart to be seen more easily during myocardial perfusion imaging.
In two main studies, around 2,000 adult patients first had a myocardial perfusion imaging scan performed using adenosine (another medicine used as a stress agent) followed by a second scan with either adenosine or Rapiscan. The main measure of effectiveness was based on the similarity between the results of the scans with Rapiscan and adenosine.
The results of scans using Rapiscan and adenosine were comparable. The ‘agreement rates’ between the first and second scans were similar regardless of which of the two medicines were used for the second scan.
The most common side effects with Rapiscan (seen in more than 1 patient in 10) are headache, dizziness, ST-segment changes (an abnormal reading on the electrocardiogram or ECG), flushing (reddening of the skin), dyspnoea (difficulty breathing), gastrointestinal (stomach and gut) discomfort and chest pain. For the full list of all side effects reported with Rapiscan, see the package leaflet.
Rapiscan must not be used in patients with slow heart rate unless they have a pacemaker, unstable angina (a type of chest pain that changes in severity) that has not been controlled with treatment, severe hypotension (low blood pressure) or decompensated heart failure (when the heart does not work as well as it should). For the full list of restrictions, see the package leaflet.
The CHMP decided that Rapiscan’s benefits are greater than its risks and recommended that it be given marketing authorisation.
A risk management plan has been developed to ensure that Rapiscan is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rapiscan, including the appropriate precautions to be followed by healthcare professionals and patients.
The European Commission granted a marketing authorisation valid throughout the European Union for Rapiscan on 6 September 2010.
For more information about treatment with Rapiscan, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Product information
Latest procedure affecting product information:
II/0041/G
30/03/2023
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Rapiscan
- Active substance
- regadenoson
- International non-proprietary name (INN) or common name
- regadenoson
- Therapeutic area (MeSH)
- Myocardial Perfusion Imaging
- Anatomical therapeutic chemical (ATC) code
- C01EB21
Pharmacotherapeutic group
Cardiac therapyTherapeutic indication
This medicinal product is for diagnostic use only.
Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
News on Rapiscan
Topics
This page was last updated on